Our data provide solid evidence that serum IgG from children with OMS and NB increases microglial activation, which induces neuronal cytolysis through the NO/sGC/PKG pathway, suggesting that the inhibitor of microglia, such as minocycline, may serve as a plausible therapeutic candidate for pediatric OMS. The gene discussed is SGCB; the disease is opsoclonus-myoclonus syndrome.